Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome.
Alcohol withdrawal
baclofen
lorazepam
Journal
Indian journal of psychiatry
ISSN: 0019-5545
Titre abrégé: Indian J Psychiatry
Pays: India
ID NLM: 0013255
Informations de publication
Date de publication:
Historique:
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
13
2
2019
Statut:
ppublish
Résumé
Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms. The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing symptoms of AWS. It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic interventions. The severity of alcohol dependence was assessed by using the Severity of Alcohol Dependence Questionnaire, and alcohol withdrawal was assessed with the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar). Sixty-six patients were randomized (baclofen Baclofen and lorazepam are comparable in efficacy and tolerability in reducing symptoms of AWS.
Sections du résumé
BACKGROUND
BACKGROUND
Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.
AIM
OBJECTIVE
The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing symptoms of AWS.
MATERIALS AND METHODS
METHODS
It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic interventions. The severity of alcohol dependence was assessed by using the Severity of Alcohol Dependence Questionnaire, and alcohol withdrawal was assessed with the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar).
RESULTS
RESULTS
Sixty-six patients were randomized (baclofen
CONCLUSION
CONCLUSIONS
Baclofen and lorazepam are comparable in efficacy and tolerability in reducing symptoms of AWS.
Identifiants
pubmed: 30745655
doi: 10.4103/psychiatry.IndianJPsychiatry_40_17
pii: IJPsy-61-60
pmc: PMC6341928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60-64Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Alcohol Clin Exp Res. 2000 Jan;24(1):58-66
pubmed: 10656194
Alcohol Clin Exp Res. 2000 Jan;24(1):67-71
pubmed: 10656195
Am J Med. 2002 Feb 15;112(3):226-9
pubmed: 11893350
Alcohol Alcohol. 2002 Sep-Oct;37(5):504-8
pubmed: 12217947
Subst Abus. 2002 Jun;23(2):83-94
pubmed: 12444353
Alcohol Clin Exp Res. 1992 Oct;16(5):955-9
pubmed: 1443434
Clin Neuropharmacol. 2003 Sep-Oct;26(5):258-62
pubmed: 14520166
Am J Med. 2006 Mar;119(3):276.e13-8
pubmed: 16490478
Lancet. 2007 Dec 8;370(9603):1915-22
pubmed: 18068515
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008502
pubmed: 21249712
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
N Engl J Med. 1985 Oct 10;313(15):951-2
pubmed: 4033728
Addiction. 1993 Feb;88(2):209-18
pubmed: 8106063
Addiction. 1994 Feb;89(2):167-74
pubmed: 8173482
JAMA. 1997 Jul 9;278(2):144-51
pubmed: 9214531